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Abstract
Purpose: Outcome measurements currently used in chronic uveitis care fail to cover the full patient perspective.
The aim of this study is to develop a conceptual model of the factors that adult patients with chronic uveitis
consider to be important when evaluating the impact of their disease and treatment.
Methods: A qualitative study design was used. Twenty chronic uveitis patients were recruited to participate in two
focus groups. Data were transcribed verbatim and analysed using thematic analysis in ATLAS.ti.
Results: Coding of the transcripts resulted in a total of 19 codes divided over five themes: 1) disease symptoms
and treatment; 2) diagnosis and treatment process; 3) impact on daily functioning; 4) emotional impact; and 5)
treatment success factors.
Conclusion: The conceptual model resulting from this study can contribute to the development of future uveitis
specific measures in adults.
Keywords: Patient reported outcome measures (MeSH), Surveys and questionnaires (MeSH), Ophthalmology
(MeSH), Quality of health care (MeSH), Qualitative research (MeSH), Quality of life (MeSH), Uveitis (MeSH)
Introduction
Chronic uveitis, a disease characterized by intraocular
inflammations, is a complex and variable eye condition
potentially leading to blindness and affecting adults in
the working age group [1]. It is often treated systemic-
ally. Patients diagnosed with chronic uveitis not only
have problems with the chronicity of the disease and
side effects of the medication, but also with the unpre-
dictability of inflammations, transient visual acuity, in-
flammatory activity changes, and sometimes unexpected
complications of the disease and the medication used
[2–4].
A previous review found high heterogeneity of out-
come measures that are currently used for the evaluation
of uveitis treatment. Common outcome measures were
classified in several domains: 1) disease activities, 2) vis-
ual function, and 3) tissue damage or other disease com-
plications. However, those clinical outcomes are limited
in the extent to which they inform us on how patients
experience the impact of their disease. For example, pa-
tients’ evaluation of their ability to conduct daily activ-
ities, such as reading and driving, are not included [5, 6].
As chronic uveitis can have a huge impact on health-
related quality of life [2–4], currently used primary out-
come measures may therefore fall short of appropriately
addressing what patients consider as most important [7].
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Commonly used instruments for patients with chronic
uveitis are the SF-36 Health Survey [8] to measure
health-related quality of life in a generic way and the 25-
item National Eye Institute Visual Function Question-
naire (NEI-VFQ-25) [6] to measure quality of life in a
domain specific way, i.e. vision-related quality of life.
However, as these instruments are not specifically devel-
oped for the complex and variable condition chronic
uveitis [9, 10], the resulting assessment may be incom-
plete. There is a disease specific instrument developed
for uveitis, EYE-Q [11], but this instrument is meant for
a paediatric population, while chronic uveitis is most
prevalent in adults.
The development of an instrument for the adult popu-
lation firstly requires understanding which factors
chronic uveitis patients consider relevant. So far, there
has been published no substantial qualitative in-depth
research effort that focused on the patient perspectives
on disease and treatment [7]. The aim of the current
study is to develop a conceptual model of the factors
that adult patients with chronic uveitis consider to be
important when evaluating the impact of their disease
and treatment. This conceptual model can contribute to
the development of future uveitis specific measures in
adults.
Methods
Study design
To determine the factors that patients with chronic uveitis
consider important when evaluating the impact of their
disease and treatment, we used a qualitative study design
based on focus group discussion [12]. Such a focus group
approach is recommended in several relevant guidelines
like those of ISPOR [13] and the FDA [14], in order to as-
sure that all factors of disease and treatment that patients
consider important are determined.
This study is part of TopZorg, a project subsidized by
the Dutch Organisation for Health Research and Devel-
opment (ZonMw). TopZorg aims to stimulate scientific
research on highly specialized care in non-academic hos-
pitals. This study has been approved by the medical eth-
ics committee METC of Erasmus Medical Center (MEC-
2017-557).
Study sample
We invited chronic uveitis patients of The Rotterdam
Eye Hospital to participate in this study. To include a
representative cross section of all chronic uveitis pa-
tients, patients were selected from the registries by
means of stratified random sampling. Strata used were
type of chronic uveitis, time since diagnose, gender and
age. The inclusion criteria were 1) diagnosed with
chronic uveitis [15] for more than 3months; 2) having
anterior segment uveitis, posterior segment uveitis, or
panuveitis. We used the Dutch reimbursement codes
502 and 503, respectively referring to anterior segment
uveitis and to posterior segment uveitis (intermediate
and posterior) and panuveitis. These codes match with
ICD-10 codes H20.x, H30.x and H44.1; 3) 18 years or
older. We excluded patients who did not have a good
command of the Dutch language. Two focus groups, one
with 9 and one with 11 participants, were conducted to
draw out different perspectives and generate discussion,
thereby allowing each person to talk in detail about their
perspective [16]. Selected patients received a letter with
study information signed by their treating ophthalmolo-
gist. They were subsequently contacted by phone and in-
vited to participate in the focus groups. Besides the
selected patients, we invited the chairman of the uveitis
patient association from the Dutch Eye Patient Associ-
ation. The chairman met the inclusion criteria. All par-
ticipants signed informed consent.
Data collection
Focus group data were collected between February 2018
and March 2018. The focus groups took place at The Rot-
terdam Eye Hospital and were chaired by a moderator
(HK). This moderator facilitated open exchange among
participants. The moderator made use of a predefined
semi-structured topic list with open-ended questions
(Additional file 1) to structure the discussion and to pre-
vent missing relevant topics. The topic list was based on a
literature review and on input from representatives of the
Dutch uveitis patient association. An observer (LK) was
present to observe non-verbal communication and sup-
port the moderator if necessary. At the start of discussion,
participants were asked to be respectful to each other, and
the moderator emphasized the importance of hearing
from every participant. The focus groups had a duration
of 2 h, including a 15min break. Focus groups were audio-
and video recorded and transcribed verbatim.
Data analysis
Thematic analysis was conducted applying a deductive
approach to theme generation. Themes were selected
based on the questions in the topic list (Additional file
1). Two researchers (LK and AS) carefully read the tran-
scripts. Each of the two independently developed a
structured analysis framework consisting of preliminary
themes and codes. They compared their frameworks to
reach consensus. Thereafter, two researchers (HK and
AS) independently indexed the transcripts line by line
according to this framework using ATLAS.ti [17].
Coders used memos for comments during coding. When
coding was finished and the code ‘other’ was used, this
code was renamed into a new or existing codename best
reflecting the contents of the otherwise uncategorised
transcripts. Coders compared their coding and discussed
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until consensus was achieved [18–20]. Subsequently, the
framework was refined by removing, adding or combin-
ing codes in order to maximise internal homogeneity
and external heterogeneity [21]. The final framework is
added in Additional file 2. After coding was finished, the
cohesion and inter-relations between codes were ana-
lysed and visually depicted in a map.
Additional external validation
After conducting two focus groups we concluded that
data saturation was achieved, i.e. no new information
emerged in the second group. As there was discussion
within the research group whether two focus groups
might look insufficient to achieve data saturation, we de-
cided to conduct an additional external validity check by
asking chronic uveitis patients to reflex on the results,
and test whether they consider the results to be
complete. Such a validity check is a recommended
method by Green & Thorogood [22]. More specifically,
we presented the findings to six members of the uveitis
patient division of the Dutch Eye Patient Association,
asking them whether they concurred with the topics in
the structured analysis matrix (Additional file 2), which
of these topics they considered to be important, and to
note missing topics.
Results
Participants
There were two focus group sessions involving 20 partic-
ipants in total. The characteristics of the participants are
described in Table 1.
Structure
Thematic analysis of the focus groups yielded five cen-
tral themes characterising factors that patients with
chronic uveitis consider to be important when evaluating
the impact of their disease: 1) disease symptoms and
characteristics; 2) diagnosis and treatment process; 3)
impact on daily functioning; 4) emotional impact; and 5)
treatment success factors. Table 2 lists those themes and
underlying codes including a summary of the content.
Theme 1 disease symptoms and treatment
The symptoms experienced and various treatment op-
tions were discussed at length. Patients reported symp-
toms related to vision and symptoms related to pain and
discomfort. The extent to which they experienced symp-
toms depended on their personal condition and differed
strongly between patients, e.g. from no vision to very
good vision and from no pain at all to unbearable pain.
Further, patients experienced difficulties attributing
symptoms to chronic uveitis, since most patients suf-
fered from comorbid conditions (comorbidity). As symp-
toms and comorbidity were different among patients,
medication use and side effects of that medication use
also differed between patients. Treatments given to pa-
tients included steroids, immunotherapy and biologicals.
Medication use received much attention in the discus-
sions. Patients were especially interested in each other’s
experiences with various types of medication, ways of
taking medication – infuse, tablet, injection, drops - and
dosage. Besides medication use, patients also mentioned
surgeries and hospitalizations, however they did so only
in relation to comorbidity and not to uveitis.
Theme 2 diagnosis and treatment process
Most patients commented that it took long until they
were correctly diagnosed with uveitis. This diagnostic
process was characterized by slow referrals from the gen-
eral practitioner to specialist care, many examinations -
of which many were unnecessary -, and even misdiag-
nosis. For instance, a patient said: “Actually, my optician
discovered it by chance. He said: there is an inflamma-
tion in your eye. Then it took me a long time to finally
get my primary care doctor’s permission. And, indeed,
examination has shown that it was sarcoidosis”.
Even when patients were diagnosed with uveitis, they
experienced a poor recognition of uveitis by the general
practitioner, emergency care physicians, and ophthal-
mology residents in cases where their own specialist was
not available. This poor recognition resulted in inad-
equate examinations and medication prescriptions or in
long time to treatment, as is illustrated by the following
Table 1 Patients’ characteristics participants’ focus group
Focus group 1 Focus group 2 Total
N 11 9 20
Women, n (%) 7 (64) 5 (56) 12 (60)
Age in years, mean (range) 56 (32–74) 53 (38–65) 55 (32–74)
Diagnose code, n (%)
- ICD-10 H20.x Anterior segment 5 (45) 5 (56) 10 (50)
- ICD-10 H30.x Posterior segment 4 (36) 2 (22) 6 (30)
- ICD-10 H44.1 Panuveitis 2 (18) 2 (22) 4 (20)
Years since diagnosis, median (range) 10 (3–13) 7 (1–14) 9 (1–14)
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quote: “And then you get there at the emergency depart-
ment. And then you get all kinds of examinations with
which you are even worse off. Sometimes also with medi-
cation that are of no use. When I get to my own ophthal-
mologist, I have the correct diagnosis and the right
medication within five minutes, and I am done within
five minutes”.
Further, patients reported that they experienced diffi-
culties in reaching their own uveitis specialist. They ex-
perienced the limited accessibility as an unnecessary
disease burden. “That you are in direct contact with him
[own uveitis specialist], [...] you just want to be able to
act quickly and now you are actually stopped by how it
is organized.“.
Theme 3 impact on daily functioning
Patients varied strongly in the impact chronic uveitis
had on their daily function, including activities such as
employment, sports, mobility, and watching TV or read-
ing. For example, one patient reported to have lost her
job because of chronic uveitis, by contrast, another pa-
tient reported to do fine with her fulltime job. Further,
patients discussed different patterns of dependency in-
cluding dependency on other people, lifelong depend-
ency on medication, and dependency on devices. To
illustrate, one patient said: “Yes, even if you just arrived
in southern France and you have to say [to your spouse]
the next morning: [we have to] go back again, because I
have to go to Rotterdam. That has happened to me
often”.
Further, the impact on daily functioning depends on
support patients experience within relationships. Some
patients experienced much understanding from their so-
cial environment, while others felt that their environ-
ment downplayed the severity of their disease which
enlarged the impact of disease burden.
Theme 4 emotional impact
Patients highlight several emotional consequences of
chronic uveitis. A main topic is the uncertainty patients
experienced because of the unpredictability of the dis-
ease. We distinguished three different kinds of uncer-
tainty. The first is uncertainty about the inflammation.
Some patients could clearly recognize an inflammation,
while others were unable to do so. Patients who experi-
ence difficulties in recognition made remarks like: “But
in this case: do I have it or not? And then you cross that
threshold to go to a doctor. That for me is the uncer-
tainty.” Secondly, there is uncertainty about the future:
the long-term effects of medication, the development of
chronic uveitis, the fear of becoming blind and questions
regarding inheritability. For instance, a patient said:
“That is really the rottenest thing I have, I think. Most
frightening [ …] and uh, yes, I am afraid that my other
eye, my good eye, will be like that too.” Lastly, patients
perceive uncertainty about causes of complaints. It in-
volves doubt about whether it is the uveitis that causes
certain complaints or whether those results from a co-
morbid disorder.
In addition, patients often named stress as an import-
ant factor. The emotional stress may be caused by the
feeling of not being taken seriously by health profes-
sionals, by lack of timely access to their own ophthal-
mologist, by experienced barriers in daily functioning, or
by the dependency caused by the chronic uveitis.
Theme 5 treatment success factors
Treatment success factors emerged as a fifth theme. Pa-
tients perceived three main treatment success factors: 1)
outcome – in terms of improvement in vision and/or quality
of life; 2) stability – in terms of happiness when the uveitis
is under control; and 3) the degree of shared decision mak-
ing between patient and ophthalmologist - in terms of hav-
ing enough time for consultation, sharing knowledge and
experiences, and being able to exert influence on decision
making on medication use. To illustrate stability, one pa-
tient mentioned: “eh I also see my treatment as very success-
ful. It has taken eight nine years, continuous bleeding, flares
and inflammations in my eye. Nerves and it all. That has
now completely calmed down. No bleeding, no inflamma-
tion. So, I am a happy person.” Medication use and side ef-
fects were important topics in shared decision making.
Patients noticed that shared decision making was not al-
ways there, whereas they would have liked otherwise to ex-
perience their treatment as successful.
Cohesion between themes and codes
The cohesion and inter-relations between themes and
codes is depicted in Fig. 1. Medication and side effects is
placed in the middle indicating its central role. It is
closely related to accessibility and shared decision mak-
ing. This is because (questions about) medication use are
an important reason for the desire for easily accessible
care and an important topic during consultations ac-
cording to patients. Further, it is notable that codes be-
longing to one and the same theme are clustered close
together, which indicates the uniformity of defined
themes (see Fig. 1). Lastly, we noticed that the code
stress came up in between codes across various themes
underwriting the importance of stress due to chronic
uveitis in patients’ daily life.
Additional external validation
Six members of the uveitis patient division of the Dutch
Eye Patient Association took part in the additional exter-
nal validity check to maximize validity (Table 3). Results
were in line with our findings and no new topics came
up.
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Discussion
This study shows a conceptual model with five themes
that patients with chronic uveitis consider to be of im-
portance when evaluating the impact of their disease
and treatment: disease symptoms and treatment, diagno-
sis and treatment process, impact on daily functioning,
emotional impact, and treatment success factors.
Therefore, we recommend these five themes to be in-
cluded in the development of future uveitis specific mea-
sures in adults.
Considering how these themes relate to the most fre-
quently used instruments, SF-36 and VFQ-25, we notice
that they only partly cover the patient perspective. The
generic SF-36 may measure the theme ‘impact on daily
function’ accurate yet fails to cover uveitis-specific out-
comes in the themes ‘disease symptoms and treatment’,
‘diagnosis and treatment process’, specific ‘emotional im-
pact’, and ‘treatment success factors’. Next, even though
the VFQ-25 distinguishes 11 vision-related subscales,
this instrument also fails to address the themes ‘diagno-
sis and treatment process’, ‘emotional consequences’ and
some of the ‘treatment success factors’ found to be of
significance for chronic uveitis by adult patients. Our
findings therefore reveal that - in addition to clinical and
Fig. 1 A summary model depicting the relationships between themes and codes
Table 3 Patients’ characteristics of members from uveitis
patient association involved in validity check
Total
N 6
Women, n (%) 4 (67)
Age in years, mean (range) 55 (43–67)
Years since diagnosis, median (range) 12 (2–30)
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quality of life outcomes - process factors are also rele-
vant when measuring the impact of this complex and
variable condition from a patient perspective.
Next to our main results, there are several findings
worth further consideration. First, we note that access to
an uveitis specialist familiar with the patient appears
highly valued by patients. A trained coordinator may be
beneficial to this purpose. Such a person may have
added value in improving accessibility, the interdisciplin-
ary monitoring of disease-activities, ensuring timely and
accurate referral and the management of in-between-
visits questions that do not require a visit to the clinic.
A second finding worth highlighting is the uncertainty
patients experience about short- and long-term disease
outcomes. Providing information and clear communica-
tion on these matters may help patients to better pre-
pare for the sometimes capricious disease course of
chronic uveitis. A third finding for further consideration
relates to the difficulties patients experience in coping
with prolonged medication. Our findings suggest that
better alignment with patients about risks and benefits
of specific types and dosages of medication may provide
patients with more control and understanding of their
treatment. That may have a positive effect on how pa-
tients evaluate the outcome of their treatment, as shared
decision making about medication can increase patients’
satisfaction [23]. This being said, we note that shared de-
cision making in case of chronic uveitis can be compli-
cated by the limited number of prospective randomized
controlled trials studying the various systemic medica-
tion treatments and the complexity of the disease.
A major strength of this study was the diversity of pa-
tients who were selected by stratified sampling from pa-
tients’ records. The methods used ensured that a wide
variety of chronic uveitis patients were included in the
focus groups. However, we also note that by deliberately
making heterogeneous groups, comparing results be-
tween subgroups becomes complex. A limitation of this
study is therefore that we can only report about the het-
erogeneous group of chronic uveitis patients as a whole
and not about subgroups e.g., patients diagnosed with
ocular sarcoidosis or Birdshot retinochoroidopathy.
In conclusion, we have proposed a conceptual model
containing five themes that are important when evaluating
the impact of chronic uveitis in adult patients. These
themes with their underlying codes can be used to develop
a disease specific measurement instrument for adult
chronic uveitis patients. With such an instrument patients’
disease experiences can be monitored and used to further
improve the care provided and their quality of life.
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